Position in GYRE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$289
+$25 QoQ
Shares Held
44
+15.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#51
of 60 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026OSAIC HOLDINGS, INC. holds $237,726,268 across 405 Biotechnology names. GYRE ranks #339 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
90,236 | $28,522,697 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
49,586 | $24,630,851 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
372,588 | $20,469,983 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
217,577 | $16,205,134 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
176,973 | $13,851,674 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
45,298 | $13,636,055 | |
| 7 | VCEL |
Vericel Corp
|
182,038 | $8,098,869 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
12,423 | $7,746,234 |
All Filings in GYRE
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $289 | 44 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $264 | 38 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $267 | 38 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $283 | 38 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $278 | 38 | Shares | Defined | 2025-09-04 | |
| 2025-03-31 | $84 | 11 | Shares | Defined | 2025-05-12 | |
| 2024-12-31 | $495 | 41 | Shares | Defined | 2025-06-06 | |
| 2024-09-30 | $5,529 | 441 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $7,647 | 641 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $244 | 14 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $359 | 14 | Shares | Sole | 2024-02-12 | |
| No filing history on record for this holder in this stock. | ||||||